The Effect of Intravenous Parecoxib on Early Ambulation After Elective Lumbar Spinal Surgery: A Propensity Score Matching Analysis

<b>Background:</b> Intravenous (IV) parecoxib could reduce pain intensity during the acute phase of lumbar spine surgery. However, details pertinent to the specific effect of this medication on promoting early patient mobility are still controversial. We aimed to investigate the effect of intravenous parecoxib on promoting early ambulation. <b>Methods:</b> This retrospective observational study included patients who underwent elective lumbar spinal fusion between January 2017 and December 2021. The electronic medical records were reviewed, and the patients were divided into two groups: those who received intravenous parecoxib and those who received routine opioid therapy. Propensity score matching (PSM) was employed. The incidence of early ambulation within 24 h after surgery. Patients in both groups were compared. <b>Results:</b> A total of 397 patients' medical records were reviewed. After one-to-one PSM, there were 125 patients in each group. The incidence of early ambulation was higher in the parecoxib group (56% vs. 40%, <i>p</i> = 0.020). The average time point at which patients could ambulate was 10.4 h earlier in the parecoxib group compared to the control group (95% CI -12.84 to -8.06, <i>p</i> < 0.001). <b>Conclusions:</b> The administration of intravenous parecoxib after lumbar spine surgery demonstrated encouraging effects on early ambulation, with patients able to get out of bed and walk within 24 h after surgery. To endorse intravenous parecoxib as a standard postoperative pain protocol for spine surgery, further investigation in randomized controlled trials should be conducted.